---
title: "SARS-CoV-2 Infection: Modulator of Pulmonary Embolism Paradigm"
date: 2021-03-01
publishDate: 2022-05-31T17:48:50.171410Z
authors: ["Mohammad Suhail Akhter", "Hassan A. Hamali", "Abdullah A. Mobarki", "Hina Rashid", "Johannes Oldenburg", "Arijit Biswas"]
publication_types: ["2"]
abstract: "Pulmonary embolism (PE) is a life-threatening complication arising from venous thromboembolism with a difficult diagnosis and treatment and is often associated with increased mortality and morbidity. PE had a significantly low incidence prior to the COVID-19 epidemic. This condition saw a sharp surge during the COVID-19 pandemic, indicating an evident viral influence on PEâ€™s pathophysiology in COVID-19 patients. The hypercoagulable state induced by the viral load seems to be the major contributor, and the classical causative factors seem to play a lesser role. PE in COVID-19 infection has become a mammoth challenge since the diagnosis is quite challenging due to overlapping symptoms, lack of prior-known predisposing risk factors, limited resources, and viral transmittance risk. Numerous factors arising out of the viral load or treatment lead to an increased risk for PE in COVID-19 patients, besides the fact that certain unknown risk factors may also contribute to the incidence of PE in COVID-19 patients. The management of PE in COVID-19 infection mainly comprises thromboprophylaxis and anticoagulant therapy with mechanical ventilation, depending on the risk stratification of the patient, with a post-COVID-19 management that prevents recurrent PE and complications. This review aims to discuss various aspects of COVID-19-infection-associated PE and major differential aspects from non-COVID-19 PE."
featured: false
publication: "*J Clin Med*"
url_pdf: "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7961449/"
doi: "10.3390/jcm10051064"
---

